Role of solute carrier transporters in pancreatic cancer: a review
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150516" target="_blank" >RIV/61989592:15110/14:33150516 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/14:10281235 RIV/00098892:_____/14:#0000747
Result on the web
<a href="http://dx.doi.org/10.2217/PGS.14.80" target="_blank" >http://dx.doi.org/10.2217/PGS.14.80</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/PGS.14.80" target="_blank" >10.2217/PGS.14.80</a>
Alternative languages
Result language
angličtina
Original language name
Role of solute carrier transporters in pancreatic cancer: a review
Original language description
Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membranetransporters and the potential applications for PDAC therapy with nucleoside analogues are summarized
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/ED0030%2F01%2F01" target="_blank" >ED0030/01/01: Biomedicine for regional development and human resources</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacogenomics
ISSN
1462-2416
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
1133-1145
UT code for WoS article
—
EID of the result in the Scopus database
—